Skip to content

A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs — October 02, 2026

October 2, 2026 · 10 min

Show notes

A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.

In this episode
  1. Higher GLP-1 costs lead to lower adherence | EurekAlert! — EurekAlert!

    Higher GLP-1 costs lead to lower adherence | EurekAlert! News Release 30-Sep-2026 # Higher GLP-1 costs lead to lower adherence Patients significantly less likely to use the weight loss medication when monthly costs exceed $75 University of Georgia Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the…

  2. Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com — Margaret O'Hara [email protected]

    Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com # Ozempic driving massive increase in New Mexico Medicaid prescription drug spending Follow Margaret O'Hara - By Margaret O'Hara [email protected] #### Margaret O'Hara Health Care Accountability Reporter - Author email ([email protected]) - Sep 29, 2026…

  3. Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace — BioSpace

    Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace # Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic…

  4. Novel amylin drug confers 10% weight loss, well tolerated — Dorothy Brooks

    # Novel amylin drug confers 10% weight loss, well tolerated Author: Erik Swain Published: 2026-09-30T00:00:00 Source: healio.com (healio.com) Language: en ## Story Novel amylin drug confers 10% weight loss, well tolerated By Erik Swain Fact checked by Richard Smith # Novel amylin drug confers 10% weight loss with adverse events comparable to placebo September 30, 2026 5 min read By…

  5. People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 — Annika Kim Constantino

    # People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 Author: NOVO NORDISK INC. Published: 2026-09-30T09:45:00+00:00 Source: prnewswire.com (prnewswire.com) Language: en ## Story People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

All episodes of GLP-1 Daily: Ozempic & Wegovy News

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.